SAHPRA Biosimilars Approval: Trends and Impact on Affordable Medicine Access

Key Takeaways

• Reliance pathway: SAHPRA uses prior assessments from stringent regulatory authorities (EMA, FDA, WHO) to streamline biosimilar reviews while maintaining independent scientific judgment [SAHPRA Reliance Guideline].
• Updated guidance: SAHPRA's biosimilar guidelines (updated December 2025) define quality, non-clinical, and clinical requirements for demonstrating similarity to reference products [SAHPRA Biosimilar Guideline].
• Market expansion: South Africa's biosimilar market is projected to grow at 19.1% CAGR through 2033, driven by affordability needs and expanded patient access.
• Regional leadership: SAHPRA's streamlined approval model serves as a reference for other African regulatory bodies through the African Medicines Regulatory Harmonization (AMRH) initiative.
• Safety monitoring: Post-market surveillance requirements align with WHO pharmacovigilance standards to ensure long-term biosimilar safety [WHO Biosimilar Guidelines].

What Is SAHPRA's Role in Biosimilar Regulation?

The South African Health Products Regulatory Authority (SAHPRA) is the national regulator for health products in South Africa. SAHPRA works in a healthcare setting where new biologics are often limited by cost and production.

Biologic therapies—including monoclonal antibodies and recombinant proteins—are vital for treating cancer, immune disorders, and chronic diseases. Biosimilars are lower-cost options that expand treatment access while meeting strict safety and efficacy standards.

SAHPRA balances the protection of innovation with the need for affordable public health solutions. In a setting where healthcare budgets are tight and out-of-pocket expenses are high, the availability of biosimilars can improve patient outcomes and support healthcare system sustainability.

How Has SAHPRA Streamlined Biosimilar Approvals Since 2018?

In 2018, SAHPRA began a major update to its biosimilar approval process. The key element was adding reliance pathways that use prior assessments from the EMA, FDA, and WHO.

The reliance pathway works as follows:

1. SAHPRA reviews the applicant's dossier alongside regulatory decisions from recognized stringent authorities
2. The authority evaluates whether the prior assessment addresses South African population-specific considerations
3. SAHPRA retains the right to request additional data relevant to local healthcare contexts
4. Final decisions incorporate independent scientific judgment while avoiding redundant reviews

This approach effectively tackled approval backlogs that limited patient access and deterred investment. By relying on established international assessments, SAHPRA has maintained rigorous oversight while expediting market entry. The reliance model has minimized administrative redundancy without sacrificing safety or efficacy assessments.

Currently, the average approval timeline stands at approximately 443 days from submission to decision. While this duration exceeds expedited pathways in some regions, it marks considerable improvement over past delays and enhances SAHPRA's competitive position within the African regulatory framework.

What Do the 2025 Biosimilar Guidelines Clarify?

SAHPRA's biosimilar guideline (Document SAHPGL-PEM-BIO-02, updated December 2025) gives guidance for companies seeking to register biosimilar drugs. The guideline covers three main areas:

Quality Requirements

The guideline requires full characterization of the reference product to define quality traits that affect clinical performance. Applicants must use sensitive physical, chemical, and functional methods—including modern and complementary approaches—for both reference product testing and comparison studies.

Non-Clinical Requirements

Animal toxicity tests are required when needed to support biosimilarity claims. The guideline states that non-clinical studies should detect any key differences between the biosimilar and reference product.

Clinical Requirements

Clinical testing focuses on pharmacokinetic (PK) and pharmacodynamic (PD) studies, plus immunogenicity tests. The guideline follows WHO guidance that analytical testing is usually more sensitive than clinical efficacy studies for finding differences between products.

How Does SAHPRA's Framework Compare Globally?

SAHPRA's biosimilar rules align with global standards while meeting African healthcare needs. The table below compares key regulatory approaches:

Comparison of Biosimilar Regulatory Approaches

Regulator	Framework	Interchangeability	Key Features
SAHPRA	Reliance pathway (2018)	Guideline-defined criteria	Uses EMA/FDA/WHO assessments; 443-day average timeline
FDA	BPCI Act (2010)	Additional switching studies required	Comparative clinical pharmacology emphasis; distinct biosimilar vs. interchangeable categories [FDA Guidance]
EMA	Biosimilar framework (2003)	All EU-approved biosimilars considered interchangeable	Comprehensive comparability exercise; multiple switches supported [EMA Q&A]
WHO	TRS 1043 Annex 3 (2022)	NRA discretion	Streamlined approach; emphasizes analytical characterization over clinical efficacy studies

SAHPRA's reliance pathway is a practical response to challenges faced by African regulators. Unlike the EMA model, which needs independent reviews, SAHPRA's approach uses prior assessments while keeping its own scientific judgment.

What Is Driving Biosimilar Market Growth in South Africa?

The South African biosimilar market is projected to reach $363.3 thousand by 2033, growing at 19.1% CAGR. This expansion is driven by three primary factors:

Affordability need: Originator biologics often cost more than South African patients, clinics, and health budgets can afford. Biosimilars usually launch at 20–40% lower prices than originators, creating major savings while matching therapeutic effect.

Regulatory clarity: The 2025 guideline updates cut approval uncertainty and help makers develop compliant programs. Clear guidance on interchangeability lets doctors and pharmacists make informed prescribing choices.

Healthcare policy fit: Provincial health departments and national insurers can shift budgets to expand access as biosimilar use grows. This cost impact is key for keeping healthcare systems running in low-resource settings.

What Are the Strategic Implications for Stakeholders?

For drug makers, SAHPRA's streamlined approval process and clear guidance cut regulatory uncertainty and invite investment. The 443-day timeline is longer than fast-track paths in developed regions, but it stays competitive for African market entry.

For doctors and pharmacists, SAHPRA's rules on interchangeability and post-market monitoring support informed prescribing. The guidelines set clear criteria for biosimilar substitution, letting providers recommend biosimilars with confidence.

For policymakers, the expected 19.1% market growth is both an opportunity and a need for health system planning. Plans for biosimilar uptake—including payment rules, buying policies, and provider training—will directly impact patient access.

How Is SAHPRA Supporting African Regulatory Harmonization?

SAHPRA's biosimilar rules act as a model for other African regulators seeking to balance innovation protection with affordable drug access. The African Medicines Regulatory Harmonization (AMRH) initiative works to align biosimilar standards across the continent.

As regulatory skills grow, mutual recognition deals and aligned guidelines may follow. WHO workshops—such as the November 2025 event in Tunis—support regulatory unity by training national regulators from across Africa in science-based biosimilar review.

Key opportunities include:

• Expansion of SAHPRA's reliance pathways to other therapeutic areas
• Harmonization of biosimilar standards through AMRH
• Development of local biosimilar manufacturing capacity
• Regional export opportunities for South African manufacturers

Frequently Asked Questions

Primary Sources

1. SAHPRA. Biosimilar Medicine Quality, Non-clinical and Clinical Requirements. Document SAHPGL-PEM-BIO-02, Version 2 (updated December 2025).
2. SAHPRA. Reliance Guideline. Document SAHPGL-BAU-01, Version 7 (updated June 2026).
3. U.S. Food and Drug Administration. Considerations in Demonstrating Interchangeability With a Reference Product. Guidance for Industry (May 2019).
4. European Medicines Agency. Q&A on the Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. EMA/93740/2023 Rev. 1 (April 2023).
5. World Health Organization. Implementation Workshop: Revised WHO Guidelines on Evaluation of Biosimilars. Tunis, Tunisia (November 2025).
6. World Health Organization. Good reliance practices in regulatory decision-making for medical products: high-level principles and considerations. Working Document QAS/20.851/Rev.1.
7. Grand View Research. South Africa Biosimilars Market Size & Outlook, 2026-2033.

Related coverage: SAHPRA Biosimilars Approval Pathway Analysis | Biosimilars Category | MEA Regulatory Coverage